The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
All triterpenoids are synthesized via the cyclization of the C30 isoprenoid chain, squalene. Eukaryotes use oxidosqualene cyclase and several other enzymes to create the tetracyclic skeleton found in steroids, a process that requires molecular oxygen. Bacteria use a similar enzyme (shc) to create the pentacyclic hopanoid precursor, diploptene; however, this biosynthesis does not require oxygen. It was recently discovered that tetrahymanol-producing bacteria form diploptene using shc then elongate the final cyclopentane into a fifth ring using tetrahymanol synthase (ths). It is unknown whether bacteria modify diploptene into other hopene molecules before creating tetrahymanol. It has also been found with a methylation at the C-3 site. Eukaryotes that live in anaerobic environments cannot synthesize their own sterols because of a lack of molecular oxygen. These organisms can gain sterols through predation. However, there can be times of sterol starvation. Tetrahymanol biosynthesis does not require oxygen, and can substitute readily for sterols. It is hypothesized that ciliates synthesize tetrahymanol in response to lack of oxygen and exogenous sterols. The gene for tetrahymanol synthase was found in the genomes of many genera of alpha-, delta-, and gammaproteobacteria, including Rhodopseudomonas, Bradyrhizobium and Methylomicrobium.
On July 16, 1945, the first atomic bomb test took place near the town of Alamogordo (New Mexico, USA). As a result of the atmospheric nuclear weapons tests carried out by the United States, the Soviet Union, France, Great Britain, and China, the Earth's atmosphere became increasingly contaminated with fission products from these tests from the 1950s onwards. The radioactive fallout landed on the earth's surface and ended up in plants and, via animal feed, in food of animal origin. Ultimately, they entered the human body and could be detected in bones and teeth as strontium-90, among other things. The radioactivity in the field was measured with a gamma scope, as shown at the air raid equipment exhibition in Bad Godesberg in 1954. Around 180 tests were carried out in 1962 alone. The extent of the radioactive contamination of the food sparked worldwide protests in the early 1960s.
==== Hydrogen ==== The isotopic reference frame of Standard Mean Ocean Water (SMOW) was established by Harmon Craig in 1961 by measuring δ2H and δ18O in samples of deep ocean water previously studied by Epstein & Mayeda (1953). Originally SMOW was a purely theoretical isotope ratio intended to represent the mean state of the deep ocean. In the initial work the isotopic ratios of deep ocean water were measured relative to NBS-1, a standard derived from the steam condensate of Potomac River water. Notably, this means SMOW was originally defined relative to NBS-1, and there was no physical SMOW solution. Following the advice of an IAEA advisory group meeting in 1966, Ray Weiss and Harmon Craig made an actual solution with the isotopic values of SMOW which they called Vienna Standard Mean Ocean Water (VSMOW). They also prepared a second hydrogen isotope reference material from firn collected at the Amundsen-Scott South Pole Station, initially called SNOW and later called Standard Light Antarctic Precipitation (SLAP). Both VSMOW and SLAP were distributed beginning in 1968. The isotopic characteristics of SLAP and NBS-1 were later evaluated by interlaboratory comparison through measurements against VSMOW (Gonfiantini, 1978). Subsequently, VSMOW and SLAP were used as the primary isotopic reference materials for the hydrogen isotope system for multiple decades. In 2006 the IAEA Isotope Hydrology Laboratory constructed new isotopic reference materials called VSMOW2 and SLAP2 with nearly identical δ2H and δ18O as VSMOW and SLAP.
Sources: en.wikipedia.org
After the end of World War II, Enewetak came under the control of the United States as part of the Trust Territory of the Pacific Islands, until the independence of the Marshall Islands in 1986. During its tenure, the United States evacuated the local residents many times, often involuntarily. The atoll was used for nuclear testing, as part of the Pacific Proving Grounds. Before testing commenced, the U.S. exhumed the bodies of United States servicemen killed in the Battle of Enewetak and returned them to the United States to be re-buried by their families. Forty-three nuclear tests were fired at Enewetak from 1948 to 1958. The first hydrogen bomb test, code-named Ivy Mike, occurred in late 1952 as part of Operation Ivy; it vaporized the islet of Elugelab and created two new elements: Fermium and Einsteinium. This test included B-17 Flying Fortress drones to fly through the radioactive cloud to test onboard samples. B-17 mother ships controlled the drones while flying within visual distance of them. In all, 16 to 20 B-17s took part in this operation, of which half were controlling aircraft and half were drones. To examine the explosion clouds of the nuclear bombs in 1957/58, several rockets (mostly from rockoons) were launched. One USAF airman, Jimmy Robinson, was lost at sea during the tests. Robinson's F-84 Thunderjet crashed and sank 3.5 miles (5.6 km) short of the island. Robinson's body was never recovered.
== Biology / Functions == Efficient presentation of antigenic peptides by MHC class I molecules provides the key signal for adaptive immune responses by cytotoxic (CD8+) T lymphocytes. In the "endogenous" antigen presentation pathway, proteins synthesized by cells undergo cytosolic degradation and some of their peptide fragments are transported to the ER, where suitable-length peptides are loaded onto MHC class I molecules. In the ER, ERAP1 shortens longer peptides to the optimal length for stable binding onto MHC class I molecules (Figure 1). ERAP1, like other APP components, is induced by interferon gamma, a cytokine inducing antigen presentation. ERAP1 preferentially trims N-extended substrates of 9-16 residues to optimally sized 8-10 residue peptides. This "molecular ruler" mechanism is unique to ERAP1. ERAP1 also functions in the presentation of extracellular antigens in the cross-presentation pathway. ERAP1 "trimming" modulates the peptide repertoire presented by MHC class I molecules and thereby shapes the adaptive immune response. In murine models, ERAAP (the murine homologue of human ERAP1) deficiency results in a strong alteration and increased immunogenicity of the peptide repertoire presented by MHC-I. Murine models with genetic deficiency for ERAAP have been instrumental for understanding the role of peptide trimming in the ER. Besides peptide trimming in the ER, ERAP1 has been proposed to perform additional functions depending on its location.
In 1924, Louis de Broglie proposed that all particles—particularly subatomic particles such as electrons—have an associated wave. Erwin Schrödinger, fascinated by this idea, developed an equation that describes an electron as a wave function instead of a point. This approach predicted many of the spectral phenomena that Bohr's model failed to explain, but it was difficult to visualize, and faced opposition. One of its critics, Max Born, proposed instead that Schrödinger's wave function did not describe the physical extent of an electron (like a charge distribution in classical electromagnetism), but rather gave the probability that an electron would, when measured, be found at a particular point. This reconciled the ideas of wave-like and particle-like electrons: the behavior of an electron, or of any other subatomic entity, has both wave-like and particle-like aspects, and whether one aspect or the other is observed depend upon the experiment. Schrödinger's wave model for hydrogen replaced Bohr's circular orbits with atomic orbitals giving only the probability of finding an electron at positions around the nucleus. The orbitals come in a variety of shapes depending on their energy level and angular momentum. The shapes of atomic orbitals are found by solving the Schrödinger equation. Analytic solutions of the Schrödinger equation are known for the hydrogen atom and hydrogen-like atoms such as the hydrogen molecular ion. Beginning with the helium atom—which contains just two electrons—numerical methods are used to solve the Schrödinger equation.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.